Warning: The NCBI web site requires JavaScript to function. more...
HER-2/neu diagnostics in breast cancer.
Carney WP, Leitzel K, Ali S, Neumann R, Lipton A.
Breast Cancer Res. 2007;9(3):207.
Related citations
Hidden HER-2/neu-positive breast cancer: how to maximize detection.
Carney WP.
IDrugs. 2009 Apr;12(4):238-42. Review.
Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
Tanner M, Järvinen P, Isola J.
Cancer Res. 2001 Jul 15;61(14):5345-8.
Discordant results obtained for different methods of HER-2/neu testing in breast cancer--a question of standardization, automation and timing.
Luftner D, Henschke P, Kafka A, Anagnostopoulos I, Wiechen K, Geppert R, Stein H, Wernecke KD, Kreienberg R, Possinger K.
Int J Biol Markers. 2004 Jan-Mar;19(1):1-13.
HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D, Gaglia A, Arapantoni-Dadioti P, Bobota A, Valavanis C, Kostopoulou V, Mylonakis N, Karabelis A, Pectasides M, Economopoulos T.
Anticancer Res. 2006 Jan-Feb;26(1B):647-53.
The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
Schippinger W, Regitnig P, Bauernhofer T, Ploner F, Hofmann G, Krippl P, Wehrschütz M, Lax S, Carney W, Neumann R, Wernecke KD, Samonigg H.
Oncol Rep. 2004 Jun;11(6):1331-6.
ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer.
Lüftner D, Cheli C, Mickelson K, Sampson E, Possinger K.
Int J Biol Markers. 2004 Jul-Sep;19(3):175-82.
Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V, Witzel I, Lück HJ, Köhler G, von Minckwitz G, Möbus V, Sattler D, Wilczak W, Löning T, Jänicke F, Pantel K, Thomssen C.
Breast Cancer Res Treat. 2004 Jul;86(1):9-18.
Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.
Ismail MF, Aly MS, Khaled HM, Mohamed HM.
Ger Med Sci. 2009 May 6;7:Doc03.
HER-2/neu expression in primary and metastatic breast cancer.
Lower EE, Glass E, Blau R, Harman S.
Breast Cancer Res Treat. 2009 Jan;113(2):301-6. Epub 2008 Feb 14.
The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
Ross JS, Fletcher JA.
Stem Cells. 1998;16(6):413-28. Review.
Change of HER-2/neu status in a subset of distant metastases from breast carcinomas.
Regitnig P, Schippinger W, Lindbauer M, Samonigg H, Lax SF.
J Pathol. 2004 Aug;203(4):918-26.
Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer.
Witzel I, Thomssen C, Krenkel S, Wilczak W, Bubenheim M, Pantel K, Neumann R, Jänicke F, Müller V.
Int J Biol Markers. 2006 Jul-Sep;21(3):131-40.
Testing for HER-2/neu in breast cancer: is fluorescence in situ hybridization superior in predicting outcome?
Yaziji H, Gown AM.
Adv Anat Pathol. 2002 Nov;9(6):338-44. Review.
Study of the measurement of serum extracellular domain of HER-2/neu protein with CLIA method.
Kuroda N, Kontani K, Kajikawa T, Taminato T.
Rinsho Byori. 2010 Jun;58(6):541-52.
Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.
Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, Carney W, Allard JW, Lipton A.
Clin Chem. 2002 Aug;48(8):1314-20.
Targeted therapy in breast cancer: the HER-2/neu gene and protein.
Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN.
Mol Cell Proteomics. 2004 Apr;3(4):379-98. Epub 2004 Feb 3. Review.
Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.
Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP.
Clin Breast Cancer. 2004 Jun;5(2):105-16. Review.
Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF, Köstler WJ, Hudelist G.
Biochim Biophys Acta. 2008 Dec;1786(2):105-13. Epub 2008 Mar 4. Review.
Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay.
Dittadi R, Zancan M, Perasole A, Gion M.
Int J Biol Markers. 2001 Oct-Dec;16(4):255-61.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on